Insider Selling: Moderna (NASDAQ:MRNA) President Sells 40,294 Shares of Stock

Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge sold 40,294 shares of the business’s stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $144.13, for a total value of $5,807,574.22. Following the completion of the sale, the president directly owned 1,525,858 shares of the company’s stock, valued at approximately $219,921,913.54. The trade was a 2.57% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Stephen Hoge also recently made the following trade(s):

• On Tuesday, September 15th, Stephen Hoge sold 40,281 shares of Moderna stock. The stock was sold at an average price of $146.07, for a total value of $5,883,845.67.

Moderna Stock Up 1.3%

MRNA traded up $1.85 during midday trading on Wednesday, hitting $145.62. 8,795,681 shares of the company’s stock traded hands, compared to its average volume of 11,582,703. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18. The company has a market cap of $58.14 billion, a PE ratio of -18.23 and a beta of 1.10. The stock’s fifty day simple moving average is $94.93 and its 200-day simple moving average is $68.18. Moderna, Inc. has a one year low of $22.28 and a one year high of $176.66.

Moderna (NASDAQ:MRNA) last posted its earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, topping the consensus estimate of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The company had revenue of $145.00 million during the quarter, compared to the consensus estimate of $102.93 million. During the same period in the previous year, the firm posted ($2.13) earnings per share. The company’s revenue for the quarter was up 2.1% compared to the same quarter last year. As a group, equities analysts anticipate that Moderna, Inc. will post -6.09 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Barclays increased their target price on shares of Moderna from $48.00 to $125.00 and gave the stock an “equal weight” rating in a research report on Monday, August 24th. Jefferies Financial Group reaffirmed a “hold” rating on shares of Moderna in a research report on Wednesday, August 19th. Loop Capital set a $135.00 price target on Moderna in a research note on Wednesday, August 19th. William Blair started coverage on Moderna in a report on Friday, August 28th. They set an “outperform” rating on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Moderna in a research note on Wednesday, September 9th. Seven analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and five have issued a Sell rating to the stock. According to MarketBeat.com, Moderna has a consensus rating of “Hold” and an average target price of $76.72.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Integrated Wealth Concepts LLC raised its holdings in Moderna by 17.0% in the 2nd quarter. Integrated Wealth Concepts LLC now owns 7,653 shares of the company’s stock worth $536,000 after acquiring an additional 1,114 shares during the period. NewEdge Advisors LLC boosted its holdings in Moderna by 208.0% during the second quarter. NewEdge Advisors LLC now owns 4,364 shares of the company’s stock valued at $306,000 after acquiring an additional 2,947 shares during the period. Baird Financial Group Inc. grew its position in shares of Moderna by 149.3% in the second quarter. Baird Financial Group Inc. now owns 11,918 shares of the company’s stock valued at $835,000 after purchasing an additional 7,137 shares during the last quarter. Waverly Advisors LLC acquired a new stake in shares of Moderna in the second quarter valued at about $243,000. Finally, Murphy Pohlad Asset Management LLC bought a new position in shares of Moderna in the second quarter worth about $268,000. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Company Profile

Moderna, Inc is a biotechnology company that develops messenger RNA (mRNA) medicines and vaccines. Its platform is designed to provide cells with instructions to produce proteins that may help prevent or treat infectious diseases, cancer and other medical conditions.

The company’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults. Moderna also maintains a pipeline of investigational programs in areas such as seasonal influenza, cytomegalovirus, oncology and rare diseases.

Founded in 2010 and headquartered in Cambridge, Massachusetts, Moderna serves markets in the United States and internationally through regulatory approvals, commercial partnerships and distribution arrangements.